Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Relistor

Methylnaltrexone Bromide

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Relistor:

 BioPortfolio Logo
Wyeth Reports Earnings Results for the 2008 Second Quarter and First Half and Raises Earnings Guidance 23rd July, 2008 Wyeth
MADISON, N.J., July 23 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today reported results for the 2008 second quarter and first half ending June 30, 2008. Worldwide net revenue increased 5% to $5
European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients 7th July, 2008
MAIDENHEAD, England, July 7 /PRNewswire/ -- Wyeth Pharmaceuticals, today 3rd July, announced that it has received EMEA marketing approval for Relistor(TM) (methylnaltrexone bromide) subcutaneous

This page has been viewed 24 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Relistor across BioPortfolio, or for Relistor Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.